5[5]peto R,et al.Design and Analysis of Randomized Clinical Trials Requiring Prolonged Observation of Each Paient.Introduction and design.Br J of Cancer 1976,34:585.
6[6]Lan K.K.G and Demets D.L.Design and Analysis of Group Sequential Test Based on the Type I Error Spending Rate Function.Biometrika 1987,74(1):149-154.
7[7]Demets D.L.and Lan K.K.G. Interim Analysis:The Alpha Spending Function Approach.Statistics In Medicine 1994,13:1341-1352.
8[8]Pocock SJ,Gekker NL and Tsiatis M.The Analysis of Multiple Endpoints in Clinical Trials.Biometrics 1987,43:487-489.
9[9]Bauer P.Multiple Testing in Clinical Trials.Statistics in Medicine 1991,10:925-937.
10[10]Whitehead J.Sequential Designs For Equivalence Studies.1996,15:2703-2715.
4Slutsky AS, Lavery JV. Data safety and monitoring boards. N Engl J Med,2004,350 : 1143-1147.
5Lan KK, Zucker DM. Sequential monitoring of clinical trials:The role of information and Brownian motion. Stat Med, 1993,12:753-765.
6Lan KK,Wittes J. The B-value:A tool for monitoring data. Biometrics, 1988,44:579-585.
7Proschan MA, Lan KK ,Wittes JT. Statistical Monitoring of Clinical Trials:A Unified Approach ( Statistics for Biology and Health). New York, N. Y. : Springer,2006:43-66.
8Moye LA. Statistical Monitoring of Clinical Trials: Fundamentals for Investigators. New York, N. Y. : Springer,2006 : 143-168.
9Cardozo L, Chapple CR, Toozs-Hobson P, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU International,2000, 85:659-664.
